ACOMPLIA / ZIMULTI (rimonabant)
 
The best in the world at the best price!
 
->Home Page Anagen.net ->Shop on line - The available products
About Generic Medicines sold by Pharmacy Online
 
Acomplia : now that a promising new prescription anti-obesity drug, rimonabant, is actually available in the U.K., Germany and 40 other countries, the launch of the most anticipated weight-loss medication since Fen-phen is generating a great deal of excitement among millions of obese and seriously overweight Americans and Europeans.

The drug, marketed in Europe as Acomplia, may ultimately be sold in the United States as Zimulti -- but that day appears several years off after an FDA advisory panel voted against sale of rimonabant in summer 2007 out of concern over its depressive side effects.

The Zimulti Acomplia Report, updated daily, will track the continuing efforts of Sanofi to get rimonabant approved for sale in the U.S. The Zimulti Acomplia Report also will provide news and reviews related to rimonabant so those eager to try this new anti-obesity drug will have the latest information on availability, weight-loss results and side-effects.

Rimonabant, discovered and developed by French pharmaceutical company Sanofi-Synthelabo, is a new drug thas has shown great promise in trials for the treatment of obesity and related metabolic risk factors.

Rimonabant is already on the market in Europe, being sold under the trade name Acomplia, and is awaiting approval in the United States.The FDA would not permit rimonabant to be sold as Acomplia in the U.S., and Sanofi is now hoping to market it in the United States as Zimulti.

Rimonabant works by blocking the CB1 receptor, one of two receptors found in a newly described physiological system called the Endocannabinoid System (EC System), believed to play a critical role in the regulation of food intake and energy expenditure.

The receptors are present on the surfaces of many cells throughout the body, including fat cells -- which are involved in lipid and glucose metabolism -- and those in the hypothalamus, the brain region that is thought to determine appetite.

Cannabinoids, chemical compounds produced by your body, latch on to the CB1 receptors, which are overactive in overweight and obese individuals, sending out a signal that prompts people to eat more. 

Researchers wondered whether a drug that halted this action might curb appetite, and in 2001, the first animal study was conducted at the National Institute of Alcohol Abuse and Alcoholism in Bethesda, Md.

In the study, genetically altered mice that lacked cannabinoid receptors ate less than their litter mates, even after 18 hours of fasting. When the normal mice were given rimonabant, which blocked their CB1 receptors, the mice reduced their food intake.

In 2002, Sanofi-Synthelabo began human tests.

Acomplia works by selectively targeting and blocking the CB1 receptors, helping normalize the over-activation of the EC system and making hunger or cigarette pangs more manageable.

Much of the excitement about Acomplia stems from early results suggesting that the blocking of signals that control cravings not only facilitates weight loss, but that it also improves cardiovascular/ metabolic risk factors in overweight/obese patients.

In the RIO-Lipids trial, weight loss was accompanied by a decrease in waist size of 3.4 inches demonstrating a significant reduction in abdominal obesity, an independent marker for heart disease.

Dramatic improvements also were reported in lipid profile with a 23% increase in HDL-cholesterol (good cholesterol) and a 15% decrease in triglycerides.

Improvements in glucose tolerance and insulin levels were also reported. Approximately half of the patients diagnosed at the start of the study with metabolic syndrome, who received the higher 20 mg daily dose of Acomplia, no longer had this condition at the conclusion of the trial.

For those interested in a detailed description of the approved use of the diet drug Acomplia (rimonabant) in Europe, the Summary of Product Characteristics (SPC) approved by the EMEA can be read by clicking here.

While Acomplia has been approved for sale in Europe, uncertainties remain about rimonabant's side effects.

Researcher Luc Van Gaal of the University Hospital in Antwerp, Belgium, said 14.5 percent of patients participating in one of the large clinical trials who were on the 20 mg dose stopped taking Acomplia due to adverse side effects. The main side effect, he said, was nausea, which affected one in eight patients.

An earlier clinical trial also had a drop-out rate due to side effects of about 15 percent.

Probably the most objective and comprehensive evaluation of side effects available at the moment is the one published as part of the approval process by European Medicines Agency (EMEA).

This was its report.

ACOMPLIA 20 mg has been evaluated for safety in approximately 2,500 patients enrolled in studies that examined the metabolic and weight loss effects in overweight and obese patients and in approximately 3,800 patients in other indications.

In placebo-controlled studies, the discontinuation rate due to adverse reactions was 15.7 % for patients receiving rimonabant. The most common adverse reactions resulting in discontinuation were: nausea, mood alteration with depressive symptoms, depressive disorders, anxiety and dizziness.

Depressive disorders were reported in 3.2% of obese patients, or overweight patients with associated risk factor(s) treated with rimonabant 20 mg. These were usually mild or moderate in severity and resulted in recovery in all cases either after corrective treatment or discontinuation of rimonabant and did not exhibit any differentiating characteristics compared to cases reported in the control groups.

The following table shows all treatment-emergent adverse reactions from four placebo-controlled studies in patients treated for weight loss and related metabolic disorders when these incidences were statistically significantly greater than the corresponding placebo rate (for events greater than or equal to 1 %) or considered clinically relevant (for events fewer than 1 %).

Classification of expected frequencies of undesirable effects:

Very common (More than 10 out of 100); Common (More than 1 in 100 but fewer than 10 in 100); Uncommon (More than 1 in 1,000 but fewer than 1 in 100); Rare (More than 1 in 10,000 but fewer than 1 in 1,000); Very rare (Fewer than 1 in 10,000), Not known (cannot be established from the available data).

Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.

System Organ

Class

Very common

 

 

Common

 

Uncommon Rare
Infections and infestations Upper respiratory tract infection Gastroenteritis  

 

 
Psychiatric disorders  

 

Depressive disorders

Mood alterations with depressive symptoms

Anxiety

Irritability

Nervousness

Sleep disorders

Insomnia

Parasomnias

 

Panic symptoms

Anger

Dysphoria

Emotional disorder

Hallucin- ations
Nervous system disorders  

 

Memory loss

Dizziness

 

Hypoaesthesia

Sciatica

Lethargy

 

 
Vascular disorders  

 

Hot flush  

 

 
Respiratory, thoracic and mediastinal disorders  

 

 

 

Hiccups  
Gastrointestinal disorders Nausea Diarrhoea

Vomiting

 

 

 

 
Skin and subcutaneous tissue disorders  

 

Pruritus

Hyperhidrosis

 

Night sweats  
Musculoskeletal and connective tissue disorders  

 

Tendonitis

Muscle cramp

Muscle spasms

 

 

 
General disorders  

 

Asthenia/fatigue

Influenza

 

 

 
Injury, Poisoning and procedural complications  

 

Fall

Contusion

Joint sprain

 

 

 

 

In clinical studies for other indications, the following additional adverse reactions were commonly reported:

− infections and infestations: sinusitis

− metabolism and nutrition disorders: anorexia, decreased appetite

− nervous system disorders: disturbance in attention

− gastrointestinal disorders: stomach discomfort, dry mouth

Acomplia Info
Van Gaal LF, Rissanen, AM, Scheen AJ, Ziegler O, Rössner S for the RIO-Europe Study Group. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular
Risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet. 2005;
Pagotto U. Pasquali R. Fighting obesity and associated risk factors by antagonising cannabinoid type 1 receptors. Lancet. 2005; 365: 1363-64.
365: 1389-97.
Marzo V, et al. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature. 2001;410:822-825.

You have to consult your doctor before the beginning of any treatment program

How to buy or to purchase online low price.

About Anagen.net  | How to advertise  |  Privacy PolicyLegal Disclaimer | Site resolution
Recommend this site to your friends  Anagen.net complete site in Italian language

Copyright Anagen.net